Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 139, Issue 1, Pages 110-116Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPRRESG7PGIAH5
Keywords
Blood filtration; Clotting factors
Categories
Funding
- Pall Medical, Covina, CA
- Pall Medical
Ask authors/readers for more resources
Leukoreduced blood components are commonly manufactured via filtration. There are specifications for the residual leukocyte content of any final cellular blood component but not for residual clotting factors. Leukoreduced and nonleukoreduced platelet-poor plasma products were manufactured from filtered vs unfiltered platelet-rich plasma, respectively, using platelet leukoreduction filters. The leukoreduced plasma showed lower levels of factor VIII (75% +/- 16% vs 88% +/- 18%, P <= .05), factor XI (86% +/- 9% vs 96% +/- 10%, P <= .01) and factor VII (87% +/- 14% vs 98% +/- 11%, P <= .01). No difference was seen with factor X factor V, or fibrinogen. Plasma filtered through a whole blood filter showed a reduction in factor V (105% +/- 12% vs 124% +/- 10%, P <= .01) but a minimal reduction in factor VIII (80% +/- 5% vs 82% +/- 6%, P = .04). Filtration can alter the residual levels of clotting factors to a variable extent in manufactured plasma, most noticeably factors V, VII, VIII, and XI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available